Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP5 | Q13451 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.33 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PDE7A | Q13946 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23009556 | 1.00 | FKBP5 (0.34) | FKBP5CRBNGRIN1GRIN2ACCR2 | |
| SCHEMBL23009678 | 1.00 | FKBP5 (0.34) | FKBP5CRBNGRIN1GRIN2ACCR2 | |
| SCHEMBL23009680 | 0.98 | GRIN1 (0.36) | FKBP5CRBNGRIN1GRIN2ACCR2 | |
| SCHEMBL23009660 | 0.98 | GRIN1 (0.36) | FKBP5CRBNGRIN1GRIN2ACCR2 | |
| SCHEMBL21225681 | 0.98 | FKBP5 (0.36) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL21225657 | 0.96 | FKBP5 (0.34) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL22975111 | 0.96 | FKBP5 (0.34) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL21225285 | 0.96 | FKBP5 (0.34) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL21225659 | 0.96 | FKBP5 (0.34) | FKBP5CRBNGRIN1GRIN2AOR51E2 | |
| SCHEMBL21238730 | 0.94 | GRIN1 (0.33) | GRIN1GRIN2AGRIN2BALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) | 2021-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210047324-A1 | SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF | GRIN1, GRIN2A, GRIN2B | FKBP5 362/4885CRBN 3123/4885GRIN1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.